About ABBV-744 as a potential therapeutic option for aggressive cancers
In Phase C, individuals will receive ABBV-744 and oral navitoclax. In Section D, contributors will obtain ABBV-744 and ruxolitinib. Individuals will receive treatment until finally illness progression or maybe the participants are not able to tolerate the study drugs.Possible new strategies with the prognosis and treatment of AML. (A) The identific